首页> 外文期刊>Antimicrobial agents and chemotherapy. >The oligo-acyl lysyl antimicrobial peptide C 12K- 2β 12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori
【24h】

The oligo-acyl lysyl antimicrobial peptide C 12K- 2β 12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori

机译:寡酰基赖氨酰抗菌肽C12K-2β12表现出双重作用机制,并表现出强大的针对幽门螺杆菌的体内功效

获取原文
获取原文并翻译 | 示例
       

摘要

Helicobacter pylori has developed antimicrobial resistance to virtually all current antibiotics. Thus, there is a pressing need to develop new anti-H. pylori therapies. We recently described a novel oligo-acyl-lysyl (OAK) antimicrobial peptidomimetic, C 12K- 2β 12, that shows potent in vitro bactericidal activity against H. pylori. Herein, we define the mechanism of action and evaluate the in vivo efficacy of C 12K- 2β 12 against H. pylori after experimental infection of Mongolian gerbils. We demonstrate using a 1-N-phenylnaphthylamine (fluorescent probe) uptake assay and electron microscopy that C 12K-2β 12 rapidly permeabilizes the bacterial membrane and creates pores that cause bacterial cell lysis. Furthermore, using nucleic acid binding assays, Western blots, and confocal microscopy, we show that C 12K- 2β 12 can cross the bacterial membranes into the cytoplasm and tightly bind to bacterial DNA, RNA, and proteins, a property that may result in inhibition of enzymatic activities and macromolecule synthesis. To define the in vivo efficacy of C 12K-2β 12, H. pylori-infected gerbils were orogastrically treated with increasing doses and concentrations of C 12K-2β 12 1 day or 1 week postinfection. The efficacy of C 12K-2β 12 was strongest in animals that received the largest number of doses at the highest concentration, indicating dose-dependent activity of the peptide (P 0.001 by analysis of variance [ANOVA]) regardless of the timing of the treatment with C 12K- 2β 12. Overall, our results demonstrate a dual mode of action of C 12K-2β 12 against the H. pylori membrane and cytoplasmic components. Moreover, and consistent with the previously reported in vitro efficacy, C 12K-2β 12 shows significant in vivo efficacy against H. pylori when used as monotherapy. Therefore, OAK peptides may be a valuable resource for therapeutic treatment of H. pylori infection.
机译:幽门螺杆菌已对几乎所有当前的抗生素产生了抗药性。因此,迫切需要开发新的抗-H。幽门螺杆菌疗法。我们最近描述了一种新型的寡酰基赖氨酰(OAK)抗菌肽模拟物C12K-2β12,它显示出对幽门螺杆菌的有效体外杀菌活性。本文中,我们定义了作用机制并评估了实验性感染蒙古沙鼠后C12K-2β12对幽门螺杆菌的体内功效。我们证明使用1-N-苯基萘胺(荧光探针)摄取测定法和电子显微镜观察,C12K-2β12迅速渗透细菌膜并产生引起细菌细胞裂解的孔。此外,使用核酸结合测定,蛋白质印迹和共聚焦显微镜,我们显示C12K-2β12可以穿过细菌膜进入细胞质并与细菌DNA,RNA和蛋白质紧密结合,这种性质可能导致抑制酶活性与大分子合成的关系。为了确定C12K-2β12的体内功效,在感染后第1天或1周以递增剂量和浓度的C12K-2β口服处理胃幽门螺杆菌感染的沙鼠。 C12K-2β12在以最高浓度接受最多剂量的动物中疗效最强,表明该肽的剂量依赖性活性(通过方差分析[ANOVA]进行分析,P <0.001),而与给药时间无关。 C12K-2β12治疗。总的来说,我们的结果证明C12K-2β12对幽门螺杆菌膜和细胞质成分具有双重作用模式。此外,与先前报道的体外功效一致,当用作单一疗法时,C12K-2β12显示出显着的针对幽门螺杆菌的体内功效。因此,OAK肽可能是治疗幽门螺杆菌感染的宝贵资源。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号